Economic evaluation of the home blood pressure telemonitoring and pharmacist case management to control hypertension (Hyperlink) trial

JACCP Journal of the American College of Clinical Pharmacy

Volumn 1, Issue 1, 2018, Pages 21-30

  Dehmer, Steven P ^a   Maciosek, Michael V ^a   Trower, Nicole K ^a   Asche, Stephen E ^a   Bergdall, Anna R ^a   Nyboer, Rachel A ^a   O'Connor, Patrick J ^a   Pawloski, Pamala A ^a   Sperl Hillen, JoAnn M ^a   Green, Beverly B ^b   Margolis, Karen L ^a  

^a HEALTHPARTNERS INSTITUTE   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

blood pressure; cost and cost analysis; cost benefit analysis; hypertension; pharmacist; pharmacoeconomics; telemedicine

Indexed keywords

LIPID;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CASE MANAGEMENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIASTOLIC BLOOD PRESSURE; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HOME MONITORING; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHARMACIST; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TELEMONITORING;

EID: 85058494521     PISSN: None     EISSN: 25749870     Source Type: Journal    
DOI: 10.1002/jac5.1001     Document Type: Article

References (51)

1. Yoon SS, Carroll MD, Fryar CD. Hypertension prevalence and control among adults: United States, 2011-2014. NCHS Data Brief. 2015;(220):1–8.
2. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: A report from the American Heart Association. Circulation. 2017;135(10):e146–e603.
3. Valderrama AL, Gillespie C, King SC, George MG, Hong Y, Gregg E. Vital signs: Awareness and treatment of uncontrolled hypertension among adults-United States, 2003-2010. MMWR Morb Mortal Wkly Rep. 2012;61:703–709.
4. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–1252.
5. Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Hypertension. 2015;65(6):1372–1407.
6. Frieden TR, Berwick DM. The "million hearts" initiative—preventing heart attacks and strokes. N Engl J Med. 2011;365(13):e27.
7. World Health Organization. A Global Brief on Hypertension: Silent Killer, Global Public Health Crisis. Geneva: World Health Organization, 2013 [cited 2018 Feb 21]. Available from: http://www.who.int/cardiovascular_diseases/publications/global_brief_hypertension/en/.
8. Patel SA, Winkel M, Ali MK, Narayan KM, Mehta NK. Cardiovascular mortality associated with 5 leading risk factors: National and state preventable fractions estimated from survey data. Ann Intern Med. 2015;163(4):245–253.
9. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation. 2011;123(8):933–944.
10. Ashman JJ, Rui P, Schappert SM. Age differences in visits to office-based physicians by adults with hypertension: United States 2013. NCHS Data Brief. 2016;(263):1–8.
11. Margolis KL, Asche SE, Bergdall AR, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: A cluster randomized clinical trial. JAMA. 2013;310(1):46–56.
12. Margolis KL, Kerby TJ, Asche SE, et al. Design and rationale for home blood pressure telemonitoring and case management to control hypertension (HyperLink): A cluster randomized trial. Contemp Clin Trials. 2012;33(4):794–803.
13. Ramsey SD, Willke RJ, Glick H, et al. Cost-effectiveness analysis alongside clinical trials II—An ISPOR Good Research Practices Task Force report. Value Health. 2015;18(2):161–172.
14. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103.
15. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. Oxford: Oxford University Press, 2014.
16. Mullahy J. Much ado about two: Reconsidering retransformation and the two-part model in health econometrics. J Health Econ. 1998;17(3):247–281.
17. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ. 1999;18(2):153–171.
18. Manning WG, Mullahy J. Estimating log models: To transform or not to transform? J Health Econ. 2001;20(4):461–494.
19. D'Agostino RB, Belanger AJ, D'Agostino RB Jr. A suggestion for using powerful and informative tests of normality. The American Statistician. 1990;44(4):316–321.
20. Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika. 1965;52(3–4):591–611.
21. Miller RG Jr. Beyond ANOVA: Basics of applied statistics. London: Chapman & Hall, 1997.
22. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73(1):13–22.
23. Raudenbush SW, Bryk AS. Hierarchical linear models: Applications and data analysis methods. 2nd ed. Thousand Oaks, CA: Sage, 2002.
24. Hosmer DW Jr, Lemeshow S, Sturdivant RX. Applied logistic regression. 3rd ed. New York, NY: John Wiley & Sons, 2013.
25. Pregibon D. Goodness of link tests for generalized linear models. Applied Statistics. 1980;29:15–24.
26. White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica. 1980;48(4):817–838.
27. Dehmer SP, Baker-Goering MM, Maciosek MV, et al. Modeled health and economic impact of team-based care for hypertension. Am J Prev Med. 2016;50, 5(suppl 1):S34–S44.
28. Jacob V, Chattopadhyay SK, Thota AB, et al. Economics of team-based care in controlling blood pressure: A community guide systematic review. Am J Prev Med. 2015;49(5):772–783.
29. Borenstein JE, Graber G, Saltiel E, et al. Physician-pharmacist comanagement of hypertension: A randomized, comparative trial. Pharmacotherapy. 2003;23(2):209–216.
30. Bunting BA, Smith BH, Sutherland SE. The Asheville project: Clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. J Am Pharm Assoc. 2008;48(1):23–31.
31. Cote I, Gregoire JP, Moisan J, Chabot I, Lacroix G. A pharmacy-based health promotion programme in hypertension: Cost-benefit analysis. Pharmacoeconomics. 2003;21(6):415–428.
32. Devine EB, Hoang S, Fisk AW, Wilson-Norton JL, Lawless NM, Louie C. Strategies to optimize medication use in the physician group practice: The role of the clinical pharmacist. J Am Pharm Assoc. 2009;49(2):181–191.
33. Eckerlund I, Jonsson E, Ryden L, Rastam L, Berglund G, Isacsson SO. Economic evaluation of a Swedish medical care program for hypertension. Health Policy. 1985;5(4):299–306.
34. Fedder DO, Chang RJ, Curry S, Nichols G. The effectiveness of a community health worker outreach program on healthcare utilization of West Baltimore City Medicaid patients with diabetes with or without hypertension. Ethn Dis. 2003;13(1):22–27.
35. Isetts BJ, Schondelmeyer SW, Artz MB, et al. Clinical and economic outcomes of medication therapy management services: The Minnesota experience. J Am Pharm Assoc. 2008;48(2):203–211.
36. Munroe WP, Kunz K, Dalmady-Israel C, Potter L, Schonfeld WH. Economic evaluation of pharmacist involvement in disease management in a community pharmacy setting. Clin Ther. 1997;19(1):113–123.
37. Carter BL, Barnette DJ, Chrischilles E, Mazzotti GJ, Asali ZJ. Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. Pharmacotherapy. 1997;17(6):1274–1285.
38. Datta SK, Oddone EZ, Olsen MK, et al. Economic analysis of a tailored behavioral intervention to improve blood pressure control for primary care patients. Am Heart J. 2010;160(2):257–263.
39. Kulchaitanaroaj P, Brooks JM, Ardery G, Newman D, Carter BL. Incremental costs associated with physician and pharmacist collaboration to improve blood pressure control. Pharmacotherapy. 2012;32(8):772–780.
40. Logan AG, Milne BJ, Achber C, Campbell WP, Haynes RB. Cost-effectiveness of a worksite hypertension treatment program. Hypertension. 1981;3(2):211–218.
41. Logan AG, Milne BJ, Flanagan PT, Haynes RB. Clinical effectiveness and cost-effectiveness of monitoring blood pressure of hypertensive employees at work. Hypertension. 1983;5(6):828–836.
42. Murray MD, Harris LE, Overhage JM, et al. Failure of computerized treatment suggestions to improve health outcomes of outpatients with uncomplicated hypertension: Results of a randomized controlled trial. Pharmacotherapy. 2004;24(3):324–337.
43. Okamoto MP, Nakahiro RK. Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic. Pharmacotherapy. 2001;21(11):1337–1344.
44. Pezzin LE, Feldman PH, Mongoven JM, McDonald MV, Gerber LM, Peng TR. Improving blood pressure control: Results of home-based post-acute care interventions. J Gen Intern Med. 2011;26(3):280–286.
45. Reed SD, Li Y, Oddone EZ, Neary AM, et al. Economic evaluation of home blood pressure monitoring with or without telephonic behavioral self-management in patients with hypertension. Am J Hypertens. 2010;23(2):142–148.
46. Wertz D, Hou L, DeVries A, et al. Clinical and economic outcomes of the Cincinnati pharmacy coaching program for diabetes and hypertension. Manag Care. 2012;21(3):44–54.
47. Billups SJ, Moore LR, Olson KL, Magid DJ. Cost-effectiveness evaluation of a home blood pressure monitoring program. Am J Manag Care. 2014;20(9):e380–e387.
48. Obreli-Neto PR, Marusic S, Guidoni CM, et al. Economic evaluation of a pharmaceutical care program for elderly diabetic and hypertensive patients in primary health care: A 36-month randomized controlled clinical trial. J Manag Care Spec Pharm. 2015;21(1):66–75.
49. Wang V, Smith VA, Bosworth HB, et al. Economic evaluation of telephone self-management interventions for blood pressure control. Am Heart J. 2012;163(6):980–986.
50. Fishman PA, Cook AJ, Anderson ML, et al. Improving BP control through electronic communications: An economic evaluation. Am J Manag Care. 2013;19(9):709–716.
51. Polgreen LA, Han J, Carter BL, et al. Cost-effectiveness of a physician-pharmacist collaboration intervention to improve blood pressure control. Hypertension. 2015;66(6):1145–1151.